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Race and Hepatitis C Management within the Veterans Administration
Abstract
Objective: To examine black-white differences in hepatitis C treatment within the Veterans Administration
(VA) and determine whether racial variation in specialty consultation explains differences in hepatitis C
treatment between blacks and whites.
Methods: We performed a retrospective cohort study of 1040 veterans meeting VA eligibility criteria for
hepatitis C treatment. We used multiple imputation to handle missing race data. Specialty consultation
was determined from the VA outpatient medical dataset and hepatitis C treatment was determined from
the VA decision support system. Conditional logistic regression was used to examine the association
between race and hepatitis C treatment as well as race and specialty consultation.
Results: There was no statistical difference in specialty consultation between blacks and whites, OR=
1.23 (95% CI, 0.85-1.78). Among 505 patients who visited a specialist, there was no statistically
significant difference in hepatitis C treatment between blacks and whites, OR= 0.55 (95% CI, 0.30-1.00).
Conclusions: Among veterans who met eligibility criteria for hepatitis C treatment there were no
statistically significant differences in specialty consultation or hepatitis C treatment by race. There was a
statistical trend towards less treatment for blacks.

Keywords
Consultation; Discrimination in medical care; Hepatitis C –Treatment; Hepatitis C virus; Treatment;
Veterans — Medical care; Veterans health

Cover Page Footnote
Funding for the study was provided by the Robert Wood Johnson Clinical Scholars Program. This program
had no involvement in the design, analysis or reporting of this study. The authors report no conflict of
interests for this study.

Authors
Joahd Toure, Joshua Metlay, Sandford Schwartz, Knashawn Morales, David Kaplan, and Peter Groeneveld

This article is available in Journal of Health Disparities Research and Practice: https://digitalscholarship.unlv.edu/
jhdrp/vol4/iss3/8

JOURNAL OF

HD
RP

Journal of Health Disparities Research and Practice
Volume 4, Number 3, Spring 2011, pp. 61-74
©2011 Center for Health Disparities Research
School of Community Health Sciences
University of Nevada, Las Vegas

Race and Hepatitis C Management within the
Veterans Administration
Joahd Touré, MD, Philadelphia VA Medical Center
Joshua Metlay, MD, PhD, Philadelphia VA Medical Center
Sandford Schwartz, University of Pennsylvania
Knashawn Morales, ScD, University of Pennsylvania
David Kaplan, MD, MS, Philadelphia VA Medical Center
Peter Groeneveld, MD, MS, Philadelphia VA Medical Center
ABSTRACT
Objective: To examine black-white differences in hepatitis C treatment within the
Veterans Administration (VA) and determine whether racial variation in specialty
consultation explains differences in hepatitis C treatment between blacks and whites.
Methods: We performed a retrospective cohort study of 1040 veterans meeting VA
eligibility criteria for hepatitis C treatment. We used multiple imputation to handle
missing race data. Specialty consultation was determined from the VA outpatient
medical dataset and hepatitis C treatment was determined from the VA decision support
system. Conditional logistic regression was used to examine the association between
race and hepatitis C treatment as well as race and specialty consultation.
Results: There was no statistical difference in specialty consultation between blacks and
whites, OR= 1.23 (95% CI, 0.85-1.78). Among 505 patients who visited a specialist, there
was no statistically significant difference in hepatitis C treatment between blacks and
whites, OR= 0.55 (95% CI, 0.30-1.00).
Conclusions: Among veterans who met eligibility criteria for hepatitis C treatment
there were no statistically significant differences in specialty consultation or hepatitis C
treatment by race. There was a statistical trend towards less treatment for blacks.
Keywords: Hepatitis C, consultation, treatment, Veterans Health

INTRODUCTION
The prevalence of hepatitis C infection within the United States is 1.8%. Most people who become
infected develop chronic infection, and chronic infection is the most common cause of liver failure
and liver transplantation in the United States (Alter, 1999; Centers for Disease Control and Prevention,
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1998). Hepatitis C virus infection is particularly important within the Veterans Administration (VA),
where the prevalence among veterans is more than twice that of the general population (Cheung,
2000; Dominitz, 2005). The VA uses nationally integrated computer information systems. These
computerized systems, along with the high prevalence of Hepatitis C, makes the VA an important
and excellent setting for studying hepatitis C management. Within VA medical centers, primary
care physicians screen for infection among those at risk by testing patients’ serum for the hepatitis
C antibody (CDC 1998; CDC, 2003; Strader, 2004), and then refer patients with positive screens to
specialists trained to treat chronic hepatitis C infection, generally a gastroenterologist or infectious
disease specialist. A quantitative hepatitis C RNA test is the gold-standard for confirming infection.
Because most primary care physicians are not trained to treat chronic hepatitis C infection, patients
typically will not receive treatment unless first evaluated by a specialist. If the specialist physician
determines that a patient is eligible (Bini, 2005) for treatment and the patient agrees, then that
patient is recommended for treatment. Treatment consists of weekly doses of interferon and daily
doses of ribavirin (Strader, 2004).
While there are some studies to the contrary (Bini, 2005), many studies indicate blacks receive
treatment for chronic hepatitis C infection less often than whites (Butt, 2007; Groom, 2008; Hall,
2004; Rousseau, 2008). This has substantial implications for health disparities for three reasons. First,
among U.S. born persons six and older, hepatitis C infection is more prevalent among blacks than
whites (3.2% vs. 1.5%) (Alter, 1999). Second, the incidence of hepatocellular carcinoma, a sequela of
untreated chronic hepatitis C infection, is increasing faster among blacks than whites (El-Serag, 2003).
Third, among patients with end stage liver disease, another sequela of untreated chronic hepatitis
C infection, blacks are underrepresented on the wait-list for liver transplantation (Seaberg, 1998).
If blacks receive treatment for chronic hepatitis C infection less often, then their burden of disease
and disease sequelae may worsen relative to other groups. Unfortunately, there are no studies which
examine the causal mechanisms of this treatment disparity despite the increased prevalence and
increasing risk of hepatitis C sequelae among blacks.
HCV management involves multiple steps: access to a clinician, blood tests, specialty consultation,
and treatment. Teasing out disparities in treatment therefore requires examining the steps leading
to treatment. Racial differences in later steps may exist because of differences in the occurrence of
previous requisite steps. If blacks receive treatment less often, it may be because blacks undergo
specialty consultation less often. We therefore hypothesized that the clinical data in the VA
information systems would reveal racial differences in the occurrence of specialty consultation as a
cause of racial differences in hepatitis C treatment.

METHODS
This study was approved by the Philadelphia VA Institutional Review Board. The Philadelphia VA IRB
was aware of the identification of HIV infected subjects in this study.
Data Source
The Veterans Health Administration is a nationally integrated healthcare system with nearly 8
million veterans enrolled. After each outpatient or inpatient encounter with the VA, the patient’s
clinical record is coded, with standardized clinical information collected and stored in VA databases.
Data for this study were obtained from three VA Medical SAS datasets: 1) The Inpatient Medical SAS
Dataset (IMD), also known as the Patient Treatment File, which includes acute care, extended care,
observation care and non-VA care records; 2) the visit and event files of the Outpatient Medical SAS
Dataset (OMD) which includes all VA ambulatory care data; and 3) the Decision Support System (DSS),
which includes pharmacy records. All datasets were extracted from the Austin Automation Center.
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Study Subjects
Using the OMD and IMD, we identified all positive hepatitis C quantitative RNA laboratory
tests generated between October 1, 1999 and March 31, 2006 from Clarksburg, WV and seven
Pennsylvania sites: Altoona, Butler, Coatesville, Erie, Lebanon, Pittsburgh, and Wilkes Barre. For those
with multiple tests, we consider only the first positive test, which we call the Initial Test. We only
included patients who saw a primary care physician after the Initial Test. We only included patients
who received at least minimal primary care. We defined minimal to be three or more visits during
the study period from October 1, 1999 to September 31, 2006. Therefore, we included patients only
if they had at least three primary care visits over the study period and had at least one primary care
visit after the Initial Test. We call the first primary care visit following the Initial Test the Index Visit.
The VA uses standard inclusion/exclusion criteria when determining eligibility for Hepatitis C
treatment (VA Centers of Excellence in Hepatitis C Research and Education, 1999), (see Inclusion/
Exclusion criteria for treatment below). Using these criteria, we excluded any patient from our study
who did not meet all of the laboratory eligibility criteria (except platelet count and thyroid indices
as they were not available in our dataset). We also excluded any patient with evidence of previous
hepatitis C treatment, patients younger than 18, and patients with HIV. The patients who met both
inclusion and exclusion criteria formed the primary cohort. We examined the primary cohort for any
association between race and specialty consultation as well as race and hepatitis C treatment. We
also examined the association between race and hepatitis C treatment among the subset of patients
in the primary cohort who received specialty consultation.
Inclusion and Exclusion Criteria for Interferon and Ribavirin Therapy
Inclusion Criteria
Anti-HCV antibody positive
Hemoglobin ≥ 13g/dL for males, Hemoglobin ≥ 12g/dL for females
White Blood Cell Count ≥ 3000/mm3
Absolute Neutrophil Count ≥ 1500mm3
Platelet Count ≥ 85,000/mm3
Total Bilirubin < 2.0mg/dL
Albumin ≥ 3.2g/dL
Serum Creatinine < 1.5mg/dL
Thyroid Stimulating Hormone - within normal limits
Exclusion Criteria
Hemoglobinopathy or hemolytic anemia
Evidence of decompensated cirrhosis: Ascites, Varices, Encephalopathy
Comorbid conditions that can interfere with treatment
CNS trauma or seizure disorder
Diabetes
COPD
Coronary Artery Disease
Congestive Heart Failure
Condition which require treatment with systemic steroids
Substance Abuse
Psychiatric Disorder
Pregnancy
Inability to comply with treatment
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Primary exposure: Race
Patient race was obtained from the IMD and the OMD. Race coding within the VA is of two types,
self-reported or recorded by clerical staff. Whenever possible we used self-reported race over that of
clerical staff. Studies on the accuracy of clerical staff race coding in VA data (Kressin, 2003) indicate
race is greater than 90% accurate when white or black race is coded. We included all patients
identified as black or white.
Outcomes
We used clinic codes from the OMD to measure specialty consultation. We considered specialty
consultation positive if it met three criteria: 1) A clinic code indicating gastroenterology or infectious
disease consultation; 2) an ICD-9 code for hepatitis C (070.51, 070.54, 070.70, 070.90); and 3) date of
service after the Index Visit. We used pharmacy records from the DSS to define hepatitis C treatment
as follows: 1) prescription for interferon or pegylated interferon occurring after specialty consultation,
or 2) interferon or pegylated interferon in combination with ribavirin occurring after specialty
consultation.
Potential Confounders
We examined data generated during the year prior to the Index Visit to obtain information on
baseline patient demographics, co-morbidities, and laboratory data. Age, gender, and VA service
connectedness were obtained from the OMD and IMD. The VA standards for determining eligibility
for hepatitis C treatment also include several exclusion criteria. VA Centers of Excellence in Hepatitis C
Research and Education, 1999) Thus, we measured and controlled for these. Using ICD-9 codes from
the OMD and IMD, we captured the following co-morbidities based on the presence of one inpatient
or two outpatient primary or secondary diagnoses: Psychiatric Disorder including: Depression
(296.20-296.39, 311), Other Affective Disorders (296.00-295.19, 296.40-296.99), Psychosis (295.00295.90), or Neurotic Disorders (300); Comorbid illness including: CNS disease (330.00- 349.00), COPD
(491.00-492.99, 496.00-496.99), Diabetes (250.00-250.99), Ischemic heart disease (410.00-414.99),
Congestive Heart Failure (428.00-428.99), and Hemoglobinopathy (282.00-283.99); Alcohol abuse
(303.00-303.93, 291.00-291.99); Substance Abuse (292.00-292.99, 304.00-304.99); Cirrhosis (571.5);
Decompensated Liver Disease (572.2-572.4, 572.8); Pregnancy (650.00); and CPT codes for Organ
Transplant generated at any time between October 1, 1999 and September 30, 2006 (50380, 33945,
33935, 32851-32854, 47135-47136). HIV infection was considered positive if a patient had a positive
HIV PCR test, or the pharmacy records from the DSS revealed prescriptions for HIV medication. From
the OMD and IMD, we obtained serum ALT, total bilirubin, albumin, hememoglobin, serum creatinine,
and white blood cell count. VA Medical Center site (VAMC) was extracted from all three datasets
and defined as the site where the majority of care took place. Both internal VA sources and external
studies have demonstrated the validity of VA databases for research (Kang, 1991; Kerr, 1999; Murphy,
2002).
Data Analysis
We used the t-test and chi-square test to compare demographic and clinical characteristics by
race. We found no pregnant patients in the cohort. We calculated unadjusted odds ratios for the
association between race and the outcomes of interest. 12.2% of the patients in our primary cohort
had missing race data (127/1040, Figure 1). Using the primary cohort we performed multiple
imputation with regression of all covariates onto ten imputed datasets to assign a racial classification
to these subjects. We then performed conditional logistic regression to determine the association
between race and specialty consultation, as well as the association between race and treatment.
We also performed conditional logistic regression to determine the association between race
and treatment among the subset that underwent specialty consultation. In each case, regression
covariates included age, race, sex, serum ALT, alcohol disorder, substance abuse, psychiatric disorder,
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and comorbid illness. We included ALT because of its importance as a marker for active hepatic
inflammation and its common use in treatment decision making (Seef, 2002; Strader, 2004). We
conditioned models on the VAMC site to control for any unmeasured factors that may differ by site or
care. Finally, because of their potential use as exclusion criteria in the decision to treat, we also looked
for modification of any associations between race and outcomes by the following terms: alcohol
disorder, substance abuse, psychiatric disorder, and comorbid illness. All data were analyzed using
the statistical package Stata 9.2.

RESULTS
Figure 1 illustrates creation of the study cohort. 2,118 persons had positive results for the
quantitative hepatitis C test. Of these, 1,691 visited a primary care physician at least three times
between October 1, 1999 and March 31, 2006, including at least one visit after the positive hepatitis
C result. Of these patients, 1,058 met our inclusion and exclusion criteria. Finally, we identified 145
people whom had missing race data or could not be classified as black or white, 127 of whom had
missing data. This yielded the primary cohort of 1040 subjects, 676 whites, 237 blacks, and 127
subjects whose race was subsequently imputed.
The demographic and clinical characteristics of the cohort are shown in Table 1. The average age
was 52.4 years and 2.5% (26/1040) were female. Decompensated liver disease was more common
among whites. Whites also had higher baseline serum Albumin, ALT, White Blood Cell counts,
Hemoglobin, and Total Bilirubin levels compared to blacks. Blacks had higher serum creatinine levels,
were more likely to have documented, psychiatric illness, and drug or alcohol related illnesses or
comorbid illneses.
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Among the 1040 patients with documented HCV infection, 505 (48.6%) subsequently underwent
specialty consultation. The median time from primary care visit to specialty consultation was 16 days
longer for blacks compared to whites (63 vs. 79). Overall, the frequency of specialty consultation
was higher for blacks than whites, but not statistically significant (59.9% vs. 53.7%, p=0.10) (Table 2).
To adjust for confounding we first imputed race for those with missing information on race. During
the creation of the initial study cohort, 145 people were identified as neither black nor white, or had
missing race data (Table 1). Of these, 127 had missing race data. After imputing the race for these 127
persons and performing conditional logistic regression to control for age, sex, service connection,
serum ALT, psychiatric disease, alcohol disorder, substance abuse, comorbid conditions, and site of
care, the adjusted difference between blacks and whites remained not significant (OR=1.22, 0.85
-1.77, p=0.27) (Table 2).
In the primary cohort of veterans with documented HCV infection 130/1040 (12.5%) subsequently
received hepatitis C treatment. The median time from primary care visit to treatment was 87
days longer for blacks compared to whites (221 days vs. 308 days). Also, the overall percentage of
veterans receiving treatment was greater for whites than blacks (26.2% vs. 13.4%, p=0.02). After
full adjustment, however, the difference between blacks and whites was not statistically significant
(OR=0.64, 0.36-1.15, p=0.14) (Table 2). Among the 505 veterans with HCV infection who subsequently
underwent specialty consultation, the frequency of hepatitis C treatment also was higher for whites
than for blacks (34.7% vs. 21.3%, p<0.01); however, after full adjustment, statistical significance was
lost and only a trend towards statistically lower odds of treatment for blacks remained (OR=0.54,
0.30-1.00, p=0.05) (Table 2).

Results of conditional logistic regression are seen in table 3. Factors associated with specialty
consultation included younger age and higher serum ALT. Substance abuse was a negative predictor
of specialty consultation. Cirrhosis was the only predictor of treatment, while substance abuse,
psychiatric disorder, and comorbid illness were either negative predictors or indicated a statistical
trend towards being negative predictors.
The results of the interaction terms are listed in table 4. In two instances, being both black and
having the disorder indicated lower odds of treatment than being black alone (alcohol disorder &
psychiatric disorder). In the other two instances, being both black and having the disorder resulted
in a higher odds of treatment than being black alone (substance abuse & comorbid illness). However,
the column entitled “p-value for interaction” indicates that race did not significantly interact with any
of the factors we studied. Thus odds of treatment for blacks with the disorders are not statistically
significant than the odds of treatment for blacks without the disorder.
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DISCUSSION
We assumed that we would find a racial difference in hepatitis C treatment between blacks and
whites. Our hypothesis was that any racial difference in hepatitis C treatment would be accounted
for by differences in differences in specialty consultation. To the contrary, this cohort of veterans
with evidence for hepatitis C infection revealed black and white veterans at most had differing rates
of hepatitis C treatment which merely trended towards statistical significance after adjusting for
potential confounders. Instead of explaining treatment differences, the opposite was true – there
was no association between race and specialty consultation. If anything, blacks were more likely to
undergo specialty consultation than whites. An analysis of the veterans who underwent specialty
consultation further revealed only a statistical trend towards significance rather accounting for any
treatment difference. These results agree with a prospective cohort study among veterans with
Hepatitis C (Bini, 2005) which also showed that race was not an independent predictor of treatment.
Our study stands in contrast to two previous retrospective cohort studies showing lower treatment
among black veterans within the VA (Butt, 2007a; Rousseau, 2008). However, our results agree with
Rousseau (2008) who found no association between race and specialty consultation. One of the
strengths of our study is the use of standard VA criteria for hepatitis C treatment to define our cohort.
Unlike some of the previous studies, each person in our cohort met inclusion laboratory criteria
for treatment. Those with exclusion criteria were controlled for in our regression analyses. By using
standard VA criteria to define our cohort we were able to ensure that only those patients who were
eligible for treatment were included. A second strength is the use of multiple imputation to address
the missing race data for a significant minority of the entire sample. Many retrospective studies which
analyze existing data either fail to mention or fail to account for missing race data. This can result in
biased results. Our use of multiple imputation, while imperfect, is considered the gold-standard for
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dealing with missing data and its potential problems.
Our finding that 55.3% of veterans had undergone specialty consultation and 12.0% were given
prescriptions for hepatitis C treatment is similar to results from other studies (Butt, 2007a; Fultz,
2003; Groom, 2008; Hall, 2004; Irving, 2006; Morril, 2005; Rousseau, 2008). The high prevalence of
co-morbidities among HCV infected veterans, including psychiatric disease, alcohol and substance
abuse, is also similar to other studies (Butt, 2007a; Fultz, 2003; Hall, 2004; Rousseau, 2008).
Both the strength of the effect size and the p-value for the association between race and treatment
increased in statistical significance between the primary cohort and the subset of patients who
underwent specialty consultation, reflecting the fact that only those were seen by specialists were
treated in our cohort. A closer look at those most likely to be treated revealed a trend towards
significantly lower odds for blacks. We do not want to simply dismiss this difference because it
is not statistically significant. The difference may be important clinically. It may be due to clinical
differences between blacks and whites we could not measure, such as the severity of disease. Our
results indicated that blacks were seen by specialists on average 16 days later than whites. While this
difference is not large, it does suggest that blacks are seeing specialists later than whites. Several
studies have indicated that blacks present for medical care with more advanced disease than whites
(Mandelblatt, 1991; Roach, 1995; Swindells, 2002; Yancy, 2003). On the other hand, our data also
could not account for potential differences in the degree of liver fibrosis by race. Some evidence
suggests black patients progress to cirrhosis more slowly than white patients (Bonacini, 2001; Wiley,
2002). If blacks in our cohort had less hepatic fibrosis, then treatment may be have been indicated
less often than for whites. Our data suggest this is a possibility, as the frequency of cirrhosis among
white patients was higher than among black patients in our cohort. Another possibility is the racial
difference in genotype prevalence. Many studies have shown lower treatment responses among
blacks than whites (Kinzie, 2001; McHutchison, 2000; Muir, 2004; Pyrsopoulos, 2001) with this
difference partly due to racial differences in genotype 1 prevalence. Blacks are infected with this
difficult to treat genotype more often than whites 88% vs. 67% (Alter, 1999). Additionally, blacks
appear to respond to hepatitis C treatment less often than whites regardless of genotype (Kinzie,
2001; Pyrsopoulos, 2001). Specialists, therefore, may be deciding to withhold treatment if the risk
of serious side-effects out-weighs the relatively low likelihood of treatment response. Alternatively,
blacks patients may decide to forgo treatment more often than whites because of the relatively
low chance of treatment success and known serious side-effects of therapy (CDC, 1998; Seef,
2002; Strader, 2004). Previous research on racial disparities in health suggests blacks have lower
preferences for certain treatments compared to whites (Ayanian, 1999; Oddone, 2002; Smith, 2002;
Whittle, 1997). In these cases, black patients prefer less invasive treatments and at times will forgo
treatment entirely. It is possible that racial differences in treatment preferences, which were not
measureable in our study, may have contributed to the trend towards statistical significance in our
results.
Other potential explanations include discrimination within the healthcare setting and physician
bias. Racial discrimination within medical care settings is well documented (Abreu, 2001; Schulman,
1999; van Ryn, 2000; Weisse, 2001). While we could not account for this in our study, the interaction
terms enable us to comment on physician bias. Uncertainty of appropriate medical care can
be a cause of racial disparities. Uncertainty can lead to racial disparities because without clear
management guidelines, decision making is more susceptible to subjectivity, stereotyping, and
biases which often operate to the detriment of minorities (Smedley, 2003). While the VA has clearly
stated HCV treatment guidelines, there are no studies that indicate how well they are followed.
The decision if and when to initiate hepatitis C treatment is sometimes unclear, as are the types of
patients who will benefit most from treatment (Seef, 2002). Patients with psychiatric illnesses, HIV,
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alcohol or substance abuse fall into a “grey” category for which the appropriateness of treatment is
uncertain. The prevalence of these disorders among hepatitis C patients is high (Butt, 2007b; El-Serag,
2002; Goulet, 2005) and was high in our cohort. We detected no significant interactions between race
and any of the factors: alcohol disorder, psychiatric disorder, substance abuse, or comorbid illness.
Had we noted a clear drop in treatment rates among blacks with these disorders compared to blacks
without these disorders, it might suggest that uncertainty was playing a stronger role. However, we
did not find this. Instead, in two instances the odds of treatment actually increased among blacks
with the disorder.
We note several limitations. Our study may not be representative of the entire VA nor other care
settings. Our sample included few women and thus the results can not be generalized in this respect.
Also, we could not capture patients who received hepatitis C consultation or treatment outside the
VA. Veterans who have the financial means to do so may seek care both within and outside the VA.
Finally, our sample size while not small is moderate in comparison to other studies.
In summary, black and white veterans in this cohort had similar odds of specialty consultation
and statistically similar odds of hepatitis C treatment. A closer examination of those most likely
to be treated revealed a trend towards significantly lower odds for blacks, suggesting specialty
consultation is an important place to examine if treatment disparities exist. While access to specialists
cannot explain any disparity, there is reason to expect that clinical differences and differences in
clinical decision making by patient’s race may contribute to this disparity and require further study.

ACKNOWLEDGEMENT
Funding for the study was provided by the Robert Wood Johnson Clinical Scholars Program. This
program had no involvement in the design, analysis or reporting of this study. The authors report no
conflict of interests for this study.

REFERENCES
Abreu, M., (2001). Theory and Research on Stereotypes and Perceptual Bias: A resource guide for
multicultural counselor trainers. The Counseling Psychologist, 29, 487-512.
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., et al., (1992). The
natural history of community acquired hepatitis C in the United States. New England Journal of
Medicine, 327, 1899–1905.
Alter, M. J., (1997). Epidemiology of hepatitis C. Hepatology, 26(Suppl 1), 62–65.
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., et. al., (1999). The
prevalence of hepatitis C virus infection in the United States,1988 through 1994. New England
Journal of Medicine, 341, 556-562.
Ayanian, J. Z., Cleary, P. D., Weissman, J. S., & Epstein, A. M., (1999). The effect of patients’ preferences
on racial differences in access to renal transplantation. New England Journal of Medicine, 341,
1661–1669.
Bini, E., Brau, N., & Currie, S., (2005). Prospective Multicenter Study of Eligibility for Antiviral Therapy
Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. American Journal of
Gastroenterology, 100, 1772-1779.
Bonacini, M., Groshen, M. D., Yu, M. C., Govindarajan, S., & Lindsay, K.L., (2001). Chronic hepatitis C in
ethnic minority patients evaluated in Los Angeles County. American Journal of Gastroenterology,

Race and Hepatitis C Management • Touré et al.

71

96, 2438–2441.
Butt, A. A., Justice, A. C., Skanderson, M., Rigsby, M. O., Good, C.B., & Kwoh, C. K., (2007a). Rate and
Predictors of Treatment Prescription for Hepatitis C. Gut, 56, 385-389.
Butt, A. A., Khan, U. A., McGinnis, K. A., Skanderson, M., & Kent, K. C., (2007b). Co-morbid medical and
psychiatric illness and substance abuse in HCV-infected and uninfected veterans. Journal of Viral
Hepatitis, 14, 890-896.
Centers for Disease Control and Prevention, (1998). Recommendations for prevention and control
of hepatitis C virus (HCV) and infection and HCV-related chronic disease. Morbidity and Mortality
Weekly Report, 47, 1-39.
Centers for Disease Control and Prevention, (2003). Guidelines for Laboratory Testing and Result
Reporting of Antibody to Hepatitis C Virus. Morbidity and Mortality Weekly Report, 52, 1-24.
Cheung, R. C., (2000). Epidemiology of Hepatitis C Virus Infection in American Veterans. American
Journal of Gastroenterology, 95, 740-747.
DiBisceglie, A. M., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J., (1991).
Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis.
Hepatology, 14, 969-974.
Dominitz, J. A., Boyko, E. J., Koepsell, T.D., Heagerty, P.J., Maynard, C., Sporleder, J. L., et. al., (2005).
Elevated Prevalence of Hepatitis C Infection In Users of United States Veterans Medical Centers.
Hepatology, 41, 88-96.
El-Serag, H. B., Kunik, M., Richardson, P., & Rabaneck, L., (2002). Psychiatric disorders among veterans
with hepatitis C infection. Gastroenterology, 123, 476-482.
El-Serag, H. B., Davila, J.A., Petersen, N. J., & McGlynn, K. A., (2003). The continuing increase in the
incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medicine,
139, 817–823.
Fultz, S. L., Justice, A. C., Butt, A. A., Rabeneck, L., Weissman, S., Rodriguez-Barradas, M., et. al., (2003).
Testing, referral and treatment patterns for hepatitis C virus coinfection in a cohort of veterans
with human immunodeficiency virus. Clinical Infectious Disease, 36, 1039-1046.
Goulet, J. L., Fultz, S. L., McGinnis, K. A., & Justice, A. C., (2005). Relative prevalence of comorbidities
and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS,
19(Suppl 3), 99–105.
Groom, H., Dieperink, E., Nelson, D. B., Garrard, J., Johnson, J. R., Ewing, S. L., et. al., (2008). Outcomes
of a Hepatitis C screening program at a large urban VA medical center. Journal of Clinical
Gastroenterology, 42, 97-106.
Hall, C. S., Charlebois, E. D., Hahn, J. A., Moss, A. R., & Bangsberg, D. R., (2004). Hepatitis C virus
infection in San Francisco’s HIV-infected urban poor. Journal of General Internal Medicine, 19, 357365.
Irving, W. L., Smith, S., Cater, R., Pugh, S., Neal, K. R., Coupland, C. A., et al., (2006). Clinical pathways for
patients with newly diagnosed hepatitis C. Journal of Viral Hepatitis. 13, 264-271.
Kang, H. K., (1991). Resources for epidemiological research in Vietnam era veteran populations
within the Department of Veterans Affairs. In Page W. F., (Ed.), Epidemiology in Military and Veteran
Populations (pp. 97-103). Washington DC: National Academy Press.
Kashner, T. M., (1998). Agreement between administrative files and written medical records: a case of

72

Journal of Health Disparities Research and Practice • Vol. 4, No. 3 • Spring 2011

the Department of Veterans Affairs. Medical Care. 36, 1324-1336.
Kerr, M. A., & Cowper, D. C., (1999). Reliability and Validity of Select Data in the National Care Database
(NPCD): A Pilot Study. VA HSR&D LIP42-061.
Kinzie, J. L., Naylor, P. H., Nathani, M, G., Peleman, R. R., Ehrinpreis, M. N., Lybik, M., et al., (2001). African
Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of
treatment response than Caucasians. Journal of Viral Hepatitis, 8, 264–269.
Koretz, R. L., Bezina, M., Polito, A. J., Quan, S., Wilber, J., Dinello, R., et. al., Non-A, non-B post transfusion
hepatitis: comparing C and non-C hepatitis. Hepatology, 17, 361–365.
Kressin, N. R., Chang, B., Hendricks, A., & Kazis, L., (2003). Agreement between administrative data and
patients’ self-reports of race/ethnicity. American Journal of Public Health, 93, 1734-1739.
Mandelblatt, J., Andrews, H., & Kerner, J., (1991). Determinants of Late Stage Diagnosis of Breast and
Cervical Cancer: The impact of age, race, social class, and hospital type. American Journal of Public
Health, 81, 646-649.
McHutchison, J. G., Poynard, T., Pianko, S., Gordon, S. C., Reid, A. E., Dienstag, J., et al. (2000). The
impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis
C. The International Hepatitis Interventional Therapy Group. Gastroenterology, 119, 1317–1323.
Morril, J. A., Shrestha, M., & Grant, R. W., (2005). Barriers to the treatment of hepatitis C. Patient,
provider, and system factors. Journal of General Internal Medicine, 20, 754-758.
Muir, A. J., Bornstein, J. D., & Killenberg, P. G., (2004). Peginterferon alfa-2b and ribavirin for the
treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of
Medicine, 350, 2265-2271.
Murphy, P. A., Cowper, D. C., Seppala, G., Stroupe, K. T., & Hynes, D. M., (2002). Veterans Health
Administration inpatient and outpatient care data: A rich resource of research data. Effective
Clinical Practice, 5, E4.
Oddone, E. Z., Horner, R. D., Johnston, D. C., Stechuchak, K., McIntyre, L., Ward, A., et. al. (2002). Carotid
endarterectomy and race: do clinical differences and patient preferences account for differences?
Stroke, 33, 2936-2943.
Pyrsopoulos, N., & Jeffers, L., (2001). Schering corporation supplemental submissions on
peginterferon alfa 2-b and ribavirin combination therapy for chronic hepatitis C to Food and Drug
Administration Center for Biologics Evaluation and Research. Clinical Liver Disease, 9, 427-438.
Pyrsopoulos, N., & Jeffers, L., (2007). Hepatitis C in African Americans. Journal of Clinical
Gastroenterology, 41, 185-193.
Roach, M., & Alexander, M., (1995). The Prognostic Significance of Race and Survival from Breast
Cancer. Journal of the National Medical Association, 87, 214-219.
Rousseau, C. M., Iaonnou, G. N., Todd-Stenberg, J. A., Sloan, K. L., Larson, M. F., Forsberg, C. W., et.
al. (2008). Racial differences in the evaluation and treatment of hepatitis C among veterans: a
retrospective cohort study. American Journal of Public Health, 98, 846-852.
Seaberg, E. C., Belle, S. H., Beringer, K. C., Schivins, J. L., & Detre, K. M., (1998). Liver transplantation in
the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry.
Clinical Transplantation, 1, 17–37.
Schulman, K., Berlin, J., & Harless, W., (1999). The Effect of Race and Sex on Physicians’
Recommendations for Cardiac Catheterization. New England Journal of Medicine, 340(8), 618-626.
Seef, L. B., Hoofnagle, J. H., (2002). National Institutes of Health consensus development conference:

Race and Hepatitis C Management • Touré et al.

73

Management of hepatitis C: 2002. Hepatology. (Suppl 1), S1.
Smedley, B. D., Stith, A. Y., & Nelson, A. R., (2003). Unequal treatment: confronting racial and ethnic
disparities in health care. Washington D.C.: National Academy Press.
Smith, D. S., Krygiel, J., Nease, R. F., Sumner, W., & Catalona, W. J., (2002). Patient Preferences for
outcomes associated with surgical management of prostate cancer. Journal of Urology, 167, 21172122.
Strader, D., Wright, T., Thomas, D., & Seeff, L., (2004). AASLD Practice Guideline: Diagnosis,
Management, and Treatment of Hepatitis C. Hepatology, 39(4), 1147-1171.
Swindells, S., Cobos, D., & Lee, N., (2002). Racial/Ethnic Differences in CD4 T-Cell Count and Viral Load
at Presentation for Medical Care and in Follow-up after HIV-1 Infection. AIDS, 16(13), 1832-1834.
Szeto, H. C., Coleman, R. K., Gholami, P., Hoffman, B. B., & Goldstein, M. K., (2002). Accuracy of
computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. American Journal
of Managed Care, 8, 37-43.
VA Centers of Excellence in Hepatitis C Research and Education. (1999). VA Treatment
recommendations for patients with chronic hepatitis C: Version 1.2.
van Ryn, M., & Burke, J., (2000). The Effect of Patient Race and Socio-Economic Status on Physicians’
Perceptions of Patients. Social Science and Medicine, 50(6), 813-828.
Weisse, C., Sorum, P., Sanders, K., & Syat, B., (2001). Do Gender and Race Affect Decisions about About
Pain Management? Journal of General Internal Medicine, 16(4), 211-217.
Whittle, J., Conigliaro, J., Good, C. B., & Joswiak, M., (1997). Do patient preferences contribute to racial
differences in cardiovascular procedure use? Journal of General Internal Medicine, 12, 267-273.
Wiley, T. E., Brown, J., & Chan, J., (2002). Hepatitis C infection in African Americans: Its Natural History
and Histological Progression. American Journal Gastroenterology, 97, 700–706.
Yancy, C., (2003). Does Race Matter in Heart Failure? American Heart Journal, 146(2), 203-206.
Yovtcheva, S. P., Rifai, M. A., Moles, J. K., Van Der Linden, B. J., (2001). Psychiatric comorbidity among
hepatitis C-positive patients. Psychosomatics, 42, 411-415.

Joahd Touré MD
Philadelphia VA Medical Center for Health Equity Research and Promotion,
University of Pennsylvania School of Medicine Division of General Internal
Medicine,
Robert Wood Johnson Clinical Scholars Program,
Leonard Davis Institute of Health Economics
Joshua Metlay MD PhD
Philadelphia VA Medical Center for Health Equity Research and Promotion,
Philadelphia VA Medical Center Division of General Internal Medicine,
University of Pennsylvania School of Medicine Division of General Internal
Medicine,
Robert Wood Johnson Clinical Scholars Program,

74

Journal of Health Disparities Research and Practice • Vol. 4, No. 3 • Spring 2011

Leonard Davis Institute of Health Economics
Sandford Schwartz
University of Pennsylvania School of Medicine Division of General Internal
Medicine,
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics,
Robert Wood Johnson Clinical Scholars Program, Leonard Davis Institute of
Health Economics
Knashawn Morales ScD
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
David Kaplan MD MS
Philadelphia VA Medical Center Division of Gastroenterology,
University of Pennsylvania School of Medicine Division of Gastroenterology,
University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
Peter Groeneveld MD MS
Philadelphia VA Medical Center for Health Equity Research and Promotion,
Philadelphia VA Medical Center Division of General Internal Medicine,
University of Pennsylvania School of Medicine Division of General Internal
Medicine,
Robert Wood Johnson Clinical Scholars Program,
Leonard Davis Institute of Health Economics
Please address reprints to the corresponding author.
Corresponding Author:
Joahd Touré
jtoure@mail.med.upenn.edu
1303B Blockley Hall
423 Guardian Drive
Philadelphia PA 19104
215-573-3982

